← Leaderboards
Zora Rogers
University Of Texas Sw Med Ctr/Dallas
$776,922
Attributed
$776,922
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $202.2K · FY2006–10$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$466,956 · 2
CDC$309,966 · 1
By mechanism
U54$382,213 · 1
U58$309,966 · 1
N01$84,743 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Jer-Tsong Hsieh$5,200,733
- Michael J Gale$70,921,035
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaChemopreventionHydroxyureaPathologic ProcessHuman SubjectBlood Disorder ChemotherapyMultiple Organ FailureLongitudinal Human StudyInfant Human (0-1 Year)Preschool Child (1-5)Clinical ResearchHuman Therapy EvaluationChildCharacteristicsCellsBaseAge-YearsCaringComplicationCollaborationsCorpora CavernosaCross-Over StudiesDouble-Blind MethodBone Turnover
Grant awards (6)
PROMOTING EDUCATION AND OUTREACH OF PERSONS WITH HEREDITARY BLOOD DISORDERS: IDEN$149,987
U58 · FY2010 · DD · contact PI
PROMOTING EDUCATION AND OUTREACH OF PERSONS WITH HEREDITARY BLOOD DISORDERS: IDEN$159,979
U58 · FY2009 · DD · contact PI
Priapism: Epidemiology, Treatment, and Secondary Prevention$202,213
U54 · FY2007 · HL · contact PI
Priapism: Epidemiology, Treatment, and Secondary Prevention$180,000
U54 · FY2006 · HL · contact PI
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL$84,743
N01 · FY2000 · HB
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL$0
N01 · FY2000 · HB